Fusion Pharmaceuticals Poised For Leadership In Targeted Cancer Therapies: Oppenheimer - Fusion Pharmaceuticals (NASDAQ:FUSN)
Oppenheimer initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), citing the company's pipeline as among the best in the space with alpha-emitter-based targeted radionuclide therapies (TRTs), with three currently in clinical development.
Jeff Jones Kyle Yang Fusion Pharmaceuticals Inc Fusion Pharmaceuticals Future Pillar Cancer Treatment
Source: benzinga.com